PROW FUSION

K130254 · Nlt Spine, Ltd. · MAX · Oct 16, 2013 · Orthopedic

Device Facts

• Record ID: K130254
• Device Name: PROW FUSION
• Applicant: Nlt Spine, Ltd.
• Product Code: MAX · Orthopedic
• Decision Date: Oct 16, 2013
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Prow-Fusion Intervertebral body fusion device is indicated for spinal fusion procedures at one or two contiguous levels from L2 through S1 in skeletally mature patients with degenerative disc disease (DDD). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by the history and radiographic studies. DDD patients may also have up to Grade I Spondylolisthesis or retrolisthesis at the involved levels. The patient may have had a previous nonfusion spinal surgery at the involved spinal level(s). The device is intended to be used with supplemental spinal fixation systems that have been cleared for use in the lumbosacral spine (e.g. posterior pedicle screw and rod systems). The device is intended to be used with autogenous bone graft. Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the Prow Fusion device. The Prow Fusion intervertebral body fusion device must be inserted using a transforaminal approach.

Device Story

Prow Fusion is an intervertebral body fusion device for transforaminal lumbar interbody fusion (TLIF). Implant consists of PEEK-OPTIMA LT1/LT2 segments and titanium alloy end segments; segments are connected by a PEEK-OPTIMA LT2 strip. During surgery, the device is inserted into the disc space and the strip is used to pull the distal segment proximally, transforming the implant into a ring-shaped, closed configuration. Used with autogenous bone graft and supplemental posterior pedicle screw/rod fixation. Operated by surgeons in a clinical/OR setting. Provides structural support to the disc space to facilitate spinal fusion, potentially alleviating discogenic back pain.

Clinical Evidence

Bench testing only. Testing included static compression, static compressive shear, static torsion, dynamic compression shear, dynamic torsion, subsidence, expulsion, and particle analysis per ASTM F2077 and ASTM F2267 standards.

Technological Characteristics

Intervertebral body fusion device; materials: PEEK-OPTIMA LT1, PEEK-OPTIMA LT2, and titanium alloy. Features titanium pins and coarse surface finish on superior/inferior segments. Form factor: modular segments that form a ring-shaped configuration in situ. Transforaminal insertion approach. Reusable delivery system instruments. Mechanical testing per ASTM F2077 and ASTM F2267.

Indications for Use

Indicated for spinal fusion at 1-2 contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD), including those with up to Grade I Spondylolisthesis or retrolisthesis and prior non-fusion surgery. Requires 6 months of failed non-operative treatment.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• NLT Prow Fusion (K112359)

Submission Summary (Full Text)

{0}------------------------------------------------

K130254, page 1 of 2

NLT SPINE Prow Fusion 510(k) Premarket Notification

# 510(k) SUMMARY

NLT SPINE's Prow Fusion

Sponsor:

NLT SPINE Ltd. 6 Yad Harutzim St. Kfar-Saba Israel 4464103

OCT 1 6 2013

Contact Person:

Eti Zinger Regulatory Affairs Director NLT SPINE Ltd. Tel: [phone] Fax: [phone] [e-mail]

Date Prepared: September 9, 2013

Name of Device: Prow Fusion

Common or Usual Name: Intervertebral body fusion device

Classification Name:

Intervertebral body fusion device 21 CFR §880.3080 Product Code MAX

### Predicate Devices

NLT Prow Fusion (K112359)

### Intended Use / Indications for Use

The Prow-Fusion Intervertebral body fusion device is indicated for spinal fusion procedures at one or two contiguous levels from L2 through S1 in skeletally mature patients with degenerative disease (DDD). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by the history and radiographic studies. DDD patients may also have up to Grade I Spondylolisthesis or retrolisthesis at the involved levels. The patient may have had a previous non-fusion spinal surgery at the involved spinal level(s).

The device is intended to be used with supplemental spinal fixation systems that have been cleared for use in the lumbosacral spine (e.g. posterior pedicle screw and rod systems). The device is intended to be used with autogenous bone graft.

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows the logo for NLT Spine. The logo consists of a stylized spine graphic on the left, followed by the text "NLTSPINE" in a bold, sans-serif font. Below "NLTSPINE" is the text "NonLinear technologies" in a smaller, less bold font. The logo is simple and modern, and it effectively communicates the company's focus on spine-related technologies.

Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the Prow Fusion device.

The Prow Fusion intervertebral body fusion device must be inserted using a transforaminal approach.

## Purpose of the Special 510(k) notice:

The Prow Fusion is a modification to NLT's previously cleared K112359 Prow Fusion.

## Technological Characteristics

The Prow Fusion Intervertbral Body Fusion Device system is comprised of two components. One component is the single-use Prow Fusion implant (intervertebral body fusion device) of various heights and the second component is a set of reusable instruments (the Prow Fusion Delivery System) used for its implantation. The implant is made from PEEK-OPTIMA® LT1 & LT2 and titanium alloy. The implant features 4 PEEK-OPTIMA® LT1 mid segments and titanium end segments. The segments has coarse surface on the superior and inferior surfaces and are attached with titanium pins.

The Prow Fusion intervertebral body fusion implant is inserted using a transforaminal approach. The proximal and the distal segments are bound together by PEEK-OPTIMA® LT2 strip. The PEEK-OPTIMA® LT2 strip is used to pull the distal seament proximally to form a ring-shaped, closed-configuration implant in the disc space.

#### Performance Data

Performance testing in bench (e.g. Static Compression Test, Static Compressive Shear Test, Static Torsion Test, Dynamic Compression Shear Test, Dynamic Torsion Test, Subsidence Test, Expulsion Test, Dynamic Compression Test, and Particle Analysis Test) per ASTM F2077 and ASTM F2267, demonstrated that the Prow Fusion is ' substantially equivalent to its predicate Prow Fusion (K112359).

#### Substantial Equivalence

The Prow Fusion is as safe and effective as its predicate device, Prow Fusion (K112359). The Prow Fusion has substantially similar indications for use and technological characteristics as compared to the predicate device. Any minor differences between the device and predicates do not raise new questions of safety and effectiveness. Further, performance testing has established that the Prow Fusion has equivalent performance and safety as compared to the claimed predicate. Thus, the device is substantially equivalent to its predicate device.

{2}------------------------------------------------

#### Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

October 16, 2013

NLT SPINE Limited % Mr. Jonathan Kahan Partner Hogan Lovells US LLP 555 Thirteenth Street. Northwest Washington, District of Columbia 20004

Re: K130254

Trade/Device Name: Prow Fusion Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: September 16, 2013 Received: September 16, 2013

Dear Mr. Kahan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

{3}------------------------------------------------

## Page 2 - Mr. Jonathan Kahan

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

Image /page/3/Picture/7 description: The image shows the name "Erin EldKeith" in a stylized font. The letters are bold and black, with some decorative elements. The name appears to be a combination of two names, "Erin" and "Keith", with the middle name "Eld" in between.

for

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Image /page/4/Picture/0 description: The image shows a logo for "NLT Spine Nonlinear Technologies". To the left of the text is a black and white image of a spine. The text is in a sans-serif font and is black.

## Indications for Use Statement

K130254 510(k) Number (if known):

Device Name: Prow Fusion

Indications for Use:

The Prow-Fusion Intervertebral body fusion device is indicated for spinal fusion procedures at one or two contiguous levels from L2 through S1 in skeletally mature patients with degenerative disc disease (DDD). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by the history and radiographic studies. DDD patients may also have up to Grade I Spondylolisthesis or retrolisthesis at the involved levels. The patient may have had a previous nonfusion spinal surgery at the involved spinal level(s).

The device is intended to be used with supplemental spinal fixation systems that have been cleared for use in the lumbosacral spine (e.g. posterior pedicle screw and rod systems). The device is intended to be used with autogenous bone graft.

Patients must have undergone a regimen of at least six (6) months of non-operative treatment prior to being treated with the Prow Fusion device.

The Prow Fusion intervertebral body fusion device must be inserted using a transforaminal approach.

Prescription Use X (Per 21 C.F.R. 801.109) AND/OR

Over-The-Counter Use (Per 21 C.F.R. 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE -- CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Anton E. Dmitriev, PhD Division of Orthopedic Devices